Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Primary Biliary Cholangitis Market’s Growth Trajectory From 2025 To 2034?
The market for primary biliary cholangitis has experienced robust growth in the past few years. Projections reveal an increase from $0.98 billion in 2024 to $1.06 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.9%. This significant increase during the historical period can be credited to heightened disease awareness, escalating global health expenditure, strategic partnerships within the healthcare industry, emphasis on patient advocacy, and government-led efforts aimed at preserving liver health.
The market for primary biliary cholangitis is poised to experience robust growth in the years to come, with expectations for it to reach a worth of $1.47 billion in 2029 and a CAGR of 8.6%. This growth projection during the forecast period can be linked to factors such as the progress in biomarker research, international initiatives dealing with rare diseases, enhanced cooperation in conducting clinical trials, and a shift towards healthcare strategies that prioritize patient needs, along with the increasing need for liver transplants. Anticipated trends during this forecast period involve progress in research related to biomarkers, heightened emphasis on non-invasive methods for diagnostics, concentration on immunomodulatory therapies in research, incorporation of artificial intelligence (AI), the use of patient-reported outcomes during clinical trials, application of telemedicine for patient care, focus on combination therapies, and the development of new treatments targeting fibrosis.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp
What External and Internal Drivers Are Contributing to the Growth of thePrimary Biliary Cholangitis Market?
The primary biliary cholangitis market is anticipated to grow, owing to the escalation in smoking. Smoking, characterized by the inhalation and exhalation of smoke from burning tobacco or other substances, is an established risk factor for liver diseases like PBC. The rise in smoking rates could prompt a higher number of individuals to seek healthcare for liver-associated complications. For example, in July 2023, Statistics Canada, a government agency in Canada, reported a 2.2% increase in cigarette production compared to June 2023. Furthermore, cigarette sales saw a 2.6% boost in June, totalling 1.4 billion units, showing a growth compared to the previous month. Hence, the growing incidence of smoking is set to fuel the expansion of the primary biliary cholangitis market.
What Segment Types Define the Primary Biliary Cholangitis Market Structure?
The primary biliary cholangitismarket covered in this report is segmented –
1) By Treatment Type: Drugs; Liver Transplantation
2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
3) By End-Users: Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies
2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Primary Biliary Cholangitis Market?
North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Primary Biliary Cholangitis Market?
In the primary biliary cholangitis market, corporate entities are prioritizing the creation of unique and niche treatments, such as orphan drugs mixed with obeticholic acid (OCA) and bezafibrates for primary biliary cholangitis (PBC) handling, to attain exclusive rights to the market. The co-mingling of OCA and bezafibrate with an orphan drug tag intends to provide a more encompassing and effective method for managing PBC therapeutics, which could potentially enhance the livelihood of those suffering from this uncommon condition. For example, In May 2023, Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, was granted orphan drug designation by the FDA for its blend of obeticholic acid (OCA) and bezafibrate, which function as a PPAR agonist and could potentially treat primary biliary cholangitis (PBC), a disease that gradually worsens the liver. The same market also approved obeticholic acid (sold under the brand name Ocaliva) for PBC use within the US.
View the full report here:
https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report
What Is the Definition of the Primary Biliary Cholangitis Market?
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model